Raj Chovatiya, MD, PhD

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

In this episode of MEDcast, expert dermatologists delve into the practical aspects of using photodynamic therapy (PDT) for treatment of actinic keratosis. Specialists are sharing their protocols, advances in PDT delivery, tips for training clinical staff and communicating with patients.

In this episode of MEDcast, expert dermatologists delve into the practical aspects of using photodynamic therapy (PDT) for treatment of actinic keratosis. Specialists are sharing their protocols, advances in PDT delivery, tips for training clinical staff and communicating with patients.

In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.

In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.

In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis.

Dermatological experts discuss challenges that are associated with the use of standard and emerging treatments in special patient population.

Experts discuss how to improve recognition and referral for rare dermatologic conditions in the ER setting.

Boni Elewski, MD, and Benjamin Kaffenberger, MD, and Carly Elston, MD, provide their clinical recommendations regarding future treatments for rare dermatological disorders.

Experts discuss spesolimab, an IL-36 inhibitor, that was recently FDA approved for treatment of GPP.

Experts discuss the use of biologics in the treatment of rare dermatologic disorders.

Dermatology experts review available treatment options for the treatment of rare dermatological disorders.

Experts discuss challenges in managing rare dermatological disorders.

Experts discuss what types of skin symptoms prompt patients to go to the emergency room.